920965-91-9

Upstream product

• 920965-88-4 4-N-[(3R,4R)-1-benzyl-4-methylpiperidin-3-yl]-4-N-methyl-3-nitropyridine-2,4-diamine 
• 6980-08-1 4-chloro-3-nitro-2-pyridinamine 
• 477600-70-7 N-(3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine 

Relevant academic research and scientific papers

Novel Hinge-Binding Motifs for Janus Kinase 3 Inhibitors: A Comprehensive Structure-Activity Relationship Study on Tofacitinib Bioisosteres

The Janus kinases (JAKs) are a family of cytosolic tyrosine kinases crucially involved in cytokine signaling. JAKs have been demonstrated to be valid targets in the treatment of inflammatory and myeloproliferative disorders, and two inhibitors, tofacitinib and ruxolitinib, recently received their marketing authorization. Despite this success, selectivity within the JAK family remains a major issue. Both approved compounds share a common 7H-pyrrolo[2,3-d]pyrimidine hinge binding motif, and little is known about modifications tolerated at this heterocyclic core. In the current study, a library of tofacitinib bioisosteres was prepared and tested against JAK3. The compounds possessed the tofacitinib piperidinyl side chain, whereas the hinge binding motif was replaced by a variety of heterocycles mimicking its pharmacophore. In view of the promising expectations obtained from molecular modeling, most of the compounds proved to be poorly active. However, strategies for restoring activity within this series of novel chemotypes were discovered and crucial structure-activity relationships were deduced. The compounds presented may serve as starting point for developing novel JAK inhibitors and as a valuable training set for in silico models.

NOVEL COMPOUNDS

The invention relates to compound of the formula (I) or its salt, wherein -R1, -R2, -R3, -R4, -R5, -M-, -X- and -Y= are as defined in the description, their use of as, medicament, the process for their preparation and use for the treatment of JAK3 mediated diseases.